The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy

Tommaso Stroffolini, Evangelista Sagnelli, Caterina Sagnelli, Antonina Smedile, Caterina Furlan, Filomena Morisco, Nicola Coppola, Angelo Andriulli, Piero Luigi Almasio

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: There is increasing awareness of HBV reactivation in HCV-RNA-positive/HBV-coinfected patients with chronic liver disease (CLD) treated with oral direct-acting antivirals (DAAs). Aim: To provide figures on the prevalence of HBV markers in HCV-RNA-positive subjects in Italy, where these findings are lacking. Methods: All subjects aged ≥18 years with CLD consecutively referring to Italian liver units located throughout country were prospectively enrolled in two national surveys in 2001 and 2014. Results: The total number of HCV-RNA-positive cases was 6984; 356 (5.1%) subjects vaccinated against HBV were excluded. A total of 6628 cases were evaluated. The prevalence rates of HBsAg, isolated anti-HBc and anti-HBc/anti-HBs-positivity were 2.9%, 8.1% and 14.7%, respectively. Among the estimated one million HCV-RNA-positive subjects in Italy, a substantial number of subjects are at risk of HBV reactivation due to DAA therapy. The prevalence of liver cirrhosis was higher than that of CLD in HBsAg-positive subjects (4.4% vs. 2.6%, p < 0.01) but not in those positive for other HBV markers. Conclusions: These findings outline the burden of HBV markers among HCV-RNA-positive subjects in Italy, where in 2017 reimbursement for DAA therapy by the National Health System became universal for all patients with chronic HCV infection. HBV vaccination coverage should be greatly extended, since nearly two thirds of subjects in this study resulted negative for any HBV marker.

Original languageEnglish
JournalDigestive and Liver Disease
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Italy
Antiviral Agents
RNA
Liver Diseases
Infection
Chronic Disease
Hepatitis B Surface Antigens
Therapeutics
Liver Cirrhosis
Vaccination
Liver
Health

Keywords

  • Chronic HCV infection
  • HBV reactivation
  • HBV/HCV coinfection
  • HCV therapy

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Stroffolini, T., Sagnelli, E., Sagnelli, C., Smedile, A., Furlan, C., Morisco, F., ... Almasio, P. L. (Accepted/In press). The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2018.09.010

The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy. / Stroffolini, Tommaso; Sagnelli, Evangelista; Sagnelli, Caterina; Smedile, Antonina; Furlan, Caterina; Morisco, Filomena; Coppola, Nicola; Andriulli, Angelo; Almasio, Piero Luigi.

In: Digestive and Liver Disease, 01.01.2018.

Research output: Contribution to journalArticle

Stroffolini, Tommaso ; Sagnelli, Evangelista ; Sagnelli, Caterina ; Smedile, Antonina ; Furlan, Caterina ; Morisco, Filomena ; Coppola, Nicola ; Andriulli, Angelo ; Almasio, Piero Luigi. / The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy. In: Digestive and Liver Disease. 2018.
@article{b648d99bfb354de88cce01f685eab6f1,
title = "The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy",
abstract = "Background: There is increasing awareness of HBV reactivation in HCV-RNA-positive/HBV-coinfected patients with chronic liver disease (CLD) treated with oral direct-acting antivirals (DAAs). Aim: To provide figures on the prevalence of HBV markers in HCV-RNA-positive subjects in Italy, where these findings are lacking. Methods: All subjects aged ≥18 years with CLD consecutively referring to Italian liver units located throughout country were prospectively enrolled in two national surveys in 2001 and 2014. Results: The total number of HCV-RNA-positive cases was 6984; 356 (5.1{\%}) subjects vaccinated against HBV were excluded. A total of 6628 cases were evaluated. The prevalence rates of HBsAg, isolated anti-HBc and anti-HBc/anti-HBs-positivity were 2.9{\%}, 8.1{\%} and 14.7{\%}, respectively. Among the estimated one million HCV-RNA-positive subjects in Italy, a substantial number of subjects are at risk of HBV reactivation due to DAA therapy. The prevalence of liver cirrhosis was higher than that of CLD in HBsAg-positive subjects (4.4{\%} vs. 2.6{\%}, p < 0.01) but not in those positive for other HBV markers. Conclusions: These findings outline the burden of HBV markers among HCV-RNA-positive subjects in Italy, where in 2017 reimbursement for DAA therapy by the National Health System became universal for all patients with chronic HCV infection. HBV vaccination coverage should be greatly extended, since nearly two thirds of subjects in this study resulted negative for any HBV marker.",
keywords = "Chronic HCV infection, HBV reactivation, HBV/HCV coinfection, HCV therapy",
author = "Tommaso Stroffolini and Evangelista Sagnelli and Caterina Sagnelli and Antonina Smedile and Caterina Furlan and Filomena Morisco and Nicola Coppola and Angelo Andriulli and Almasio, {Piero Luigi}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.dld.2018.09.010",
language = "English",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy

AU - Stroffolini, Tommaso

AU - Sagnelli, Evangelista

AU - Sagnelli, Caterina

AU - Smedile, Antonina

AU - Furlan, Caterina

AU - Morisco, Filomena

AU - Coppola, Nicola

AU - Andriulli, Angelo

AU - Almasio, Piero Luigi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: There is increasing awareness of HBV reactivation in HCV-RNA-positive/HBV-coinfected patients with chronic liver disease (CLD) treated with oral direct-acting antivirals (DAAs). Aim: To provide figures on the prevalence of HBV markers in HCV-RNA-positive subjects in Italy, where these findings are lacking. Methods: All subjects aged ≥18 years with CLD consecutively referring to Italian liver units located throughout country were prospectively enrolled in two national surveys in 2001 and 2014. Results: The total number of HCV-RNA-positive cases was 6984; 356 (5.1%) subjects vaccinated against HBV were excluded. A total of 6628 cases were evaluated. The prevalence rates of HBsAg, isolated anti-HBc and anti-HBc/anti-HBs-positivity were 2.9%, 8.1% and 14.7%, respectively. Among the estimated one million HCV-RNA-positive subjects in Italy, a substantial number of subjects are at risk of HBV reactivation due to DAA therapy. The prevalence of liver cirrhosis was higher than that of CLD in HBsAg-positive subjects (4.4% vs. 2.6%, p < 0.01) but not in those positive for other HBV markers. Conclusions: These findings outline the burden of HBV markers among HCV-RNA-positive subjects in Italy, where in 2017 reimbursement for DAA therapy by the National Health System became universal for all patients with chronic HCV infection. HBV vaccination coverage should be greatly extended, since nearly two thirds of subjects in this study resulted negative for any HBV marker.

AB - Background: There is increasing awareness of HBV reactivation in HCV-RNA-positive/HBV-coinfected patients with chronic liver disease (CLD) treated with oral direct-acting antivirals (DAAs). Aim: To provide figures on the prevalence of HBV markers in HCV-RNA-positive subjects in Italy, where these findings are lacking. Methods: All subjects aged ≥18 years with CLD consecutively referring to Italian liver units located throughout country were prospectively enrolled in two national surveys in 2001 and 2014. Results: The total number of HCV-RNA-positive cases was 6984; 356 (5.1%) subjects vaccinated against HBV were excluded. A total of 6628 cases were evaluated. The prevalence rates of HBsAg, isolated anti-HBc and anti-HBc/anti-HBs-positivity were 2.9%, 8.1% and 14.7%, respectively. Among the estimated one million HCV-RNA-positive subjects in Italy, a substantial number of subjects are at risk of HBV reactivation due to DAA therapy. The prevalence of liver cirrhosis was higher than that of CLD in HBsAg-positive subjects (4.4% vs. 2.6%, p < 0.01) but not in those positive for other HBV markers. Conclusions: These findings outline the burden of HBV markers among HCV-RNA-positive subjects in Italy, where in 2017 reimbursement for DAA therapy by the National Health System became universal for all patients with chronic HCV infection. HBV vaccination coverage should be greatly extended, since nearly two thirds of subjects in this study resulted negative for any HBV marker.

KW - Chronic HCV infection

KW - HBV reactivation

KW - HBV/HCV coinfection

KW - HCV therapy

UR - http://www.scopus.com/inward/record.url?scp=85055095397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055095397&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2018.09.010

DO - 10.1016/j.dld.2018.09.010

M3 - Article

AN - SCOPUS:85055095397

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

ER -